FIBRINOGEN AND CEREBROVASCULAR-DISEASE

被引:25
作者
QIZILBASH, N
机构
关键词
FIBRINOGEN; STROKE; TRANSIENT ISCHEMIC ATTACK; GERIATRIC; FIBRATE; TREATMENT;
D O I
10.1093/eurheartj/16.suppl_A.42
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The importance of fibrinogen has been identified in two prospective observational studies. Reactive elevations in fibrinogen levels that occur within hours of a major stroke invalidate most cross-sectional case-control studies evaluating fibrinogen as a risk factor. However, as no elevation is seen following fresh episodes of transient ischaemic attacks, reliable conclusions drawn from a case-control study using such patients support the findings of the prospective studies. The association is related to occlusive stroke, but the relationship with intracerebral haemorrhage is unclear. The relationship has been found to be independent of other haemostatic and haemorheological factors (e.g. von Willebrand factor, tissue plasminogen activator and packed cell volume). Adjustment for regression dilution bias would further strengthen the observed relationship. Therefore, after blood pressure, fibrinogen is the most important potentially treatable risk factor for ischaemic stroke. There are several mechanisms whereby fibrinogen could promote atherothromboembolism: thrombosis through a hypercoagulable state; the acceleration of atherosclerosis; or the reduction of blood flow due to high blood or plasma viscosity. The mechanism, however, is unlikely to be mediated through high blood viscosity per se as secondary erythrocytosis (another major determinant of blood viscosity) has not consistently been found to be a risk factor for stroke. Studies relating fibrinogen levels to the degree of carotid artery stenosis support the accelerating influence of fibrinogen on atherosclerosis. Fibrinogen should be considered a risk factor for ischaemic stroke and included in the assessment of individual risk factors. For stroke prevention, individuals with high fibrinogen values but no other risk factors should be considered for therapies to reduce the overall risk of future stroke, i.e. blood pressure reduction and antiplatelet therapy, as well as regular exercise, weight loss and possibly the adoption of a vegetarian diet.
引用
收藏
页码:42 / 46
页数:5
相关论文
共 39 条
  • [1] THE FIBRINOLYTIC SYSTEM AND COAGULATION DURING BEZAFIBRATE TREATMENT OF HYPERTRIGLYCERIDEMIA
    ALMER, LO
    KJELLSTROM, T
    [J]. ATHEROSCLEROSIS, 1986, 61 (01) : 81 - 85
  • [2] CORRELATES OF MIDDLE CEREBRAL-ARTERY BLOOD VELOCITY IN THE ELDERLY
    AMERISO, SF
    PAGANINIHILL, A
    MEISELMAN, HJ
    FISHER, M
    [J]. STROKE, 1990, 21 (11) : 1579 - 1583
  • [3] HEMORHEOLOGIC AND COAGULATIVE PATTERN IN HYPERCHOLESTEROLEMIC SUBJECTS TREATED WITH LIPID-LOWERING DRUGS
    BO, M
    BONINO, F
    NEIROTTI, M
    GOTTERO, M
    PERNIGOTTI, L
    MOLASCHI, M
    FABRIS, F
    [J]. ANGIOLOGY, 1991, 42 (02) : 106 - 113
  • [4] CAIMI G, 1988, BRIT J CLIN PRACT, V42, P456
  • [5] THE EFFECTS OF CLOFIBRATE ON PLASMA-GLUCOSE, LIPOPROTEINS, FIBRINOGEN, AND OTHER BIOCHEMICAL AND HEMATOLOGICAL VARIABLES IN PATIENTS WITH MATURE ONSET DIABETES-MELLITUS
    CALVERT, GD
    BLIGHT, L
    FRANKLIN, J
    OLIVER, J
    WISE, P
    GALLUS, AS
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1980, 17 (05) : 355 - 362
  • [6] CAVESTRI R, 1992, ACTA NEUROL SCAND, V85, P292
  • [7] COOK NS, 1991, THROMB HAEMOSTASIS, V65, P902
  • [8] DRUGS AFFECTING PLASMA-FIBRINOGEN LEVELS
    DIMINNO, G
    MANCINI, M
    [J]. CARDIOVASCULAR DRUGS AND THERAPY, 1992, 6 (01) : 25 - 27
  • [9] SELECTIVE REMOVAL OF LOW-DENSITY LIPOPROTEINS (LDL) BY PRECIPITATION AT LOW PH - 1ST CLINICAL-APPLICATION OF THE HELP SYSTEM
    EISENHAUER, T
    ARMSTRONG, VW
    WIELAND, H
    FUCHS, C
    SCHELER, F
    SEIDEL, D
    [J]. KLINISCHE WOCHENSCHRIFT, 1987, 65 (04): : 161 - 168
  • [10] FIBRINOGEN CHANGES IN RELATION TO CEREBROVASCULAR ACCIDENTS
    ELLIOTT, FA
    BUCKELL, M
    [J]. NEUROLOGY, 1961, 11 (02) : 120 - &